SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)

Clinical trial NCT04079166 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04079166
Sponsor: Scancell Ltd
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Malignant Melanoma Melanoma (Skin)Melanoma Stage III Melanoma Stage IV

Start date: 2019-08-19
Primary completion: 2027-01-31
Enrollment: 173

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.